Original Research J Clin Psychiatry June 2023

The Effect of Lurasidone on Anxiety Symptoms in Patients With Bipolar Depression: A Post Hoc Analysis

JCP 2023;84(4):10.4088/JCP.22m14732

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2023;84(4):10.4088/JCP.22m14732 Clinical Summary Anxiety symptoms and sleep disturbance are common during bipolar depression and add clinical burden, yet clinicians often have little bipolar-specific evidence to guide treatment of these symptoms. This analysis asks a practical question: when treating bipolar I depression with lurasidone, how much improvement occurs in psychic and somatic anxiety, and does reduced sleep identify patients with a stronger anxiolytic response? FAQ Did lurasidone improve anxiety symptoms in patients with bipolar I depression? 9 questions
Key Takeaways Lurasidone separated from placebo on both anxiety domains over 6 weeks in bipolar I depression, with larger placebo-corrected differences for psychic anxiety than somatic anxiety in both monotherapy and adjunctive treatment. 6 takeaways Clinical Guide How should clinicians assess anxiety symptoms and sleep disturbance before starting lurasidone for bipolar I depression? 6 steps Clinical Guide How should clinicians monitor anxiety, sleep, and functioning during a 6-week lurasidone trial for bipolar I depression? 6 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe